Repare Therapeutics

Synthetic Lethal Therapeutics

Also 3 additional trials Clin1/Clin2 solid tumors; RP-6306 3 trials Clin1/Clin2 solid tumors; 4 undisclosed programs RD/Clin0 oncology, undisclosed

Repare Therapeutics is using the concept of synthetic lethality to develop novel medicines in oncology. Synthetic lethality refers to cases where perturbations in two targets results in death, while perturbations in either one is viable. Repare is using their innovative SNIPRx platform that uses CRISPR-screening technology to identify novel synthetic lethality targets against clinically relevant genomic alterations in tumors. Once targets are selected, Repare can then design selective small molecule inhibitors of these targets. Currently, Repare has advanced a robust clinical pipeline with their lead program, RP-6306, in clinical trials.